Stock Market News for October 6, 2026

At a glance

On October 6, 2026, Marathon Petroleum said the G7 will release up to 100 million barrels of emergency fuel stocks; Penguin Solutions reported Q4 net sales of $567 million and raised fiscal 2027 outlook; BridgeBio got FDA Priority Review for oral infigratinib with a Feb. 4, 2027 action date; Enliven reached FDA alignment on its ENABLE-2 Phase 3 design.

Commodities and energy

MARATHON PETROLEUM (MPC) reported second-quarter net income of $5.1 billion and said the G7 agreed to release up to 100 million barrels of emergency fuel stocks over four months, with substantial diesel volumes available within the first 20 days.

Earnings and guidance

Penguin Solutions (PENG) reported fourth-quarter net sales of $567 million, operating income of $69 million and net income of $93 million, and raised its fiscal 2027 sales outlook to approximately $2.43 billion at the midpoint.

Neogen (NEOG) reported fiscal 2027 first-quarter revenue of $222.8 million, up 6.5% year over year, raised annual guidance, and said adjusted EBITDA rose to $41.6 million.

RPM International (RPM) reported record fiscal 2027 first-quarter sales of $2.22 billion, net income of $256.4 million and diluted EPS of $2.01, with adjusted EBITDA of $405.5 million.

Lamb Weston Holdings (LW) reported first-quarter net sales of $1.67 billion, said net income fell to $29 million, and raised its fiscal 2027 outlook to expect sales growth in the low single digits and adjusted EBITDA of $1.125 billion to...

Constellation Brands (STZ) reported second-quarter fiscal 2027 financial results and scheduled a conference call for October 7, 2026, with management to discuss the results and outlook.

ZIM Integrated Shipping Services (ZIM) raised full-year 2026 guidance, updating expected adjusted EBITDA to $2.7 billion to $3.0 billion and expected adjusted EBIT to $1.4 billion to $1.7 billion.

Drug trials and regulatory

BridgeBio Pharma (BBIO) announced FDA acceptance and Priority Review of its NDA for oral infigratinib for children with achondroplasia, with a February 4, 2027 target action date and Phase 3 PROPEL 3 primary endpoint showing an adjusted treatment difference of +1.74 cm/year in annualized height velocity.

ArriVent BioPharma (AVBP) announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed the primary endpoint: median PFS was 11.0 months at 240mg and 8.4 months at 160mg versus 9.5 months with control, with the 240mg comparison p=0.0654.

Kairos Pharma (KAPA) reported statistically significant interim efficacy from its Phase 2 trial of ENV-105 plus apalutamide in metastatic prostate cancer, with median progression-free survival of 17.7 months for the combination versus 2 months for apalutamide alone (P=0.0008).

Enliven Therapeutics (ELVN) reached FDA alignment on the ENABLE-2 Phase 3 trial design for relcobatinib, a randomized study of ~450 adults previously treated with TKIs, with primary endpoint major molecular response at Week 24 and a key secondary at Week 96.

60 Degrees Pharmaceuticals (SXTP) said it will end enrollment in its severe babesiosis trial at 30 patients and plans a data readout in January 2027 after an independent review recommended completing planned enrollment of 33 patients.

Deals, M&A and financings

Navitas Semiconductor (NVTS) closed acquisition of Claros, adding integrated voltage regulator technology to its AI infrastructure power portfolio and saying the deal helps more than double its identified 2030 serviceable addressable market to over $8 billion.

Zeta Global Holdings (ZETA) entered into an agreement to acquire Digital Audience to expand its identity and activation capabilities and add a team of data and AI engineers to its technical organization; terms were not disclosed.

TORM (TRMD) announced pricing of a secondary public offering of 6,329,874 Class A common shares by OCM Njord Holdings for gross proceeds of about $253.5 million, expected to close on October 7, 2026; TORM will receive no proceeds.

WISeSat.Space Holdings (SAIQ) closed a $10 million private investment in public equity led by SEALSQ on Oct. 1, 2026, concurrent with its business combination, to advance satellite infrastructure and post-quantum cryptography integration.

Alpha Compute (ALP) signed a binding $71.9 million compute agreement on September 30, 2026, for its ALPHA-02 cluster in Sweden, expecting the Master Services Agreement to add $24 million in new annual contracted revenue.

Corporate actions and compliance

Global Engine Group Holding (GLE) announced a 1-for-10 share consolidation, with split-adjusted trading beginning October 8, 2026, reducing Class A shares outstanding from 16,060,000 to approximately 1,606,000.

Top Wealth Group Holding (TWG) received a Nasdaq minimum bid price notification after closing bids below US$1.00 for 30 consecutive business days and has until March 31, 2027 to regain compliance by maintaining a closing bid of at least US$1.00 for 10 consecutive business days.

Accuray (ARAY) secured stockholder approval of financing-related proposals enabling completion of its transactions with TCW, including exchanging $40 million of term loan debt for convertible preferred stock and a $15 million equity investment, plus covenant relief through Dec. 31, 2027.